-
1
-
-
0035041926
-
Antipsychotic-induced weight gain: A review of the literature
-
Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62(Suppl 7):22-31.
-
(2001)
J Clin Psychiatry
, vol.62
, Issue.SUPPL. 7
, pp. 22-31
-
-
Allison, D.B.1
Casey, D.E.2
-
4
-
-
0005221430
-
Aripiprazole vs. placebo in the treatment of stable, chronic schizophrenia
-
Jun 23-27, Montreal
-
Carson WH, Pigott TA, Saha AR, et al. Aripiprazole vs. placebo in the treatment of stable, chronic schizophrenia [Poster]. XXIII CINP Congress, 2002: Jun 23-27, Montreal.
-
(2002)
XXIII CINP Congress
-
-
Carson, W.H.1
Pigott, T.A.2
Saha, A.R.3
-
5
-
-
0037393107
-
Switching patient to aripiprazole from other antipsychotic agents: A multicenter randomized study
-
Im Druck
-
Casey DE, Carson WH, Saha AR, Liebeskind A, et al., on behalf of the Aripiprazole Study Group. Switching patient to aripiprazole from other antipsychotic agents: A multicenter randomized study. Psychopharmacology 2003. Im Druck.
-
(2003)
Psychopharmacology
-
-
Casey, D.E.1
Carson, W.H.2
Saha, A.R.3
Liebeskind, A.4
-
6
-
-
0005169169
-
Neurocognitive effects of aripiprazole vs. olanzapine in stable psychosis
-
Jun 23-27, Montreal
-
Comblatt B, Kern BS, Carson WH, et al. Neurocognitive effects of aripiprazole vs. olanzapine in stable psychosis [Poster]. XXIII CINP Congress, 2002: Jun 23-27, Montreal.
-
(2002)
XXIII CINP Congress
-
-
Comblatt, B.1
Kern, B.S.2
Carson, W.H.3
-
7
-
-
0002050453
-
Aripiprazole, a novel antipsychotic: Overview of a phase II study result
-
Daniel DG, Saha AR, Ingenito G, et al. Aripiprazole, a novel antipsychotic: overview of a phase II study result [Abstract no. P.01.242]. Int J Neuropsychopharmacol 2000;3(Suppl 1): S157.
-
(2000)
Int J Neuropsychopharmacol
, vol.3
, Issue.SUPPL. 1
-
-
Daniel, D.G.1
Saha, A.R.2
Ingenito, G.3
-
8
-
-
0026611392
-
The regulation of subcortical dopamine systems by the prefrontal cortex: Interactions of central dopamine systems and the pathogenesis of schizophrenia
-
Deutch AY. The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm Suppl 1992;36:61-89.
-
(1992)
J Neural Transm Suppl
, vol.36
, pp. 61-89
-
-
Deutch, A.Y.1
-
9
-
-
0026751059
-
Dopaminergic mechanisms in the pathogenesis of schizophrenia
-
Goldstein M, Deutch AY. Dopaminergic mechanisms in the pathogenesis of schizophrenia. FASEB J 1992;6:2413-21.
-
(1992)
FASEB J
, vol.6
, pp. 2413-2421
-
-
Goldstein, M.1
Deutch, A.Y.2
-
11
-
-
0038142977
-
Sicherheit und verträglichkeit von aripiprazol
-
DGPPN 2002
-
Hippius H, Medori R, Kungel M, Saha AR, et al. Sicherheit und Verträglichkeit von Aripiprazol [Poster]. DGPPN 2002; Nervenarzt 2002;73(Suppl 1):190.
-
(2002)
Nervenarzt
, vol.73
, Issue.SUPPL. 1
, pp. 190
-
-
Hippius, H.1
Medori, R.2
Kungel, M.3
Saha, A.R.4
-
12
-
-
0031577960
-
2 receptors following repeated treatment in the rat striatum
-
2 receptors following repeated treatment in the rat striatum. Eur J Pharmacol 1997;321:105-11.
-
(1997)
Eur J Pharmacol
, vol.321
, pp. 105-111
-
-
Inoue, A.1
Miki, S.2
Seto, M.3
-
13
-
-
0037177358
-
The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1 α receptor
-
Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1 α receptor. Eur J Pharmacol 2002;441:137-40.
-
(2002)
Eur J Pharmacol
, vol.441
, pp. 137-140
-
-
Jordan, S.1
Koprivica, V.2
Chen, R.3
-
14
-
-
0036738786
-
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder
-
Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:1-9.
-
(2002)
J Clin Psychiatry
, vol.63
, pp. 1-9
-
-
Kane, J.M.1
Carson, W.H.2
Saha, A.R.3
-
15
-
-
0012336529
-
Aripiprazole for long-term maintenance treatment of schizophrenia
-
Jun 23-27, Montreal
-
Kujawa M, Saha A, Ingenito G, Ali M, et al. Aripiprazole for long-term maintenance treatment of schizophrenia [Poster]. XXIII CINP Congress, 2002 Jun 23-27, Montreal.
-
(2002)
XXIII CINP Congress
-
-
Kujawa, M.1
Saha, A.2
Ingenito, G.3
Ali, M.4
-
16
-
-
0012336529
-
Aripiprazol for long-term maintenance treatment of schizophrenia
-
Philadelphia; Abstract NR376
-
Kujawa M, Saha A, Ingenito GG, Ali M, et al. Aripiprazol for long-term maintenance treatment of schizophrenia. APA Annual Meeting 2002, Philadelphia; Abstract NR376.
-
(2002)
APA Annual Meeting
-
-
Kujawa, M.1
Saha, A.2
Ingenito, G.G.3
Ali, M.4
-
17
-
-
0033151286
-
Interactions of the novel antipsychotic aripiprazole with dopamine and serotonin receptor sub-types
-
Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole with dopamine and serotonin receptor sub-types. Neuropsychopharmacology 1999;20:612-27.
-
(1999)
Neuropsychopharmacology
, vol.20
, pp. 612-627
-
-
Lawler, C.P.1
Prioleau, C.2
Lewis, M.M.3
-
18
-
-
0037410337
-
Aripiprazole in the treatment of schizophrenia: Safety and tolerability in short-term placebo-controlled trials
-
Im Druck
-
Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term placebo-controlled trials. Schizophr Res 2003. Im Druck.
-
(2003)
Schizophr Res
-
-
Marder, S.R.1
McQuade, R.D.2
Stock, E.3
-
20
-
-
0242614131
-
Aripiprazole: A dopamine-serotonin system stabilizer
-
Jun 23-27, Montreal
-
McQuade RD, Burris KD, Jordan S, et al. Aripiprazole: a dopamine-serotonin system stabilizer [Poster]. XXIII CINP Congress 2002 Jun 23-27, Montreal.
-
(2002)
XXIII CINP Congress
-
-
McQuade, R.D.1
Burris, K.D.2
Jordan, S.3
-
21
-
-
0036859532
-
2-agonismus und dopaminerge stabilisierung, der neuartige wirkungsmechanismus des atypischen neuroleptikums aripiprazol
-
2-Agonismus und dopaminerge Stabilisierung, der neuartige Wirkungsmechanismus des atypischen Neuroleptikums Aripiprazol. Psychopharmakotherapie 2002;9:120-7.
-
(2002)
Psychopharmakotherapie
, vol.9
, pp. 120-127
-
-
Müller, W.E.1
-
23
-
-
0001612909
-
Aripiprazole, a novel antipsychotic: Phase 2 clinical trial result
-
Petrie JL, Saha AR, McEvoy JP. Aripiprazole, a novel antipsychotic: phase 2 clinical trial result [Abstract no. P.2.114]. Eur Neuropsychopharmacol 1997;7(Suppl 2):S227.
-
(1997)
Eur Neuropsychopharmacol
, vol.7
, Issue.SUPPL. 2
-
-
Petrie, J.L.1
Saha, A.R.2
McEvoy, J.P.3
-
24
-
-
0038819745
-
Aripiprazole versus placebo in the treatment of stable, chronic schizophrenia
-
Philadelphia; Abstract NR314
-
Pigott TA, Saha AR, Ali MW, et al. Aripiprazole versus placebo in the treatment of stable, chronic schizophrenia. APA Annual Meeting 2002, Philadelphia; Abstract NR314.
-
(2002)
APA Annual Meeting
-
-
Pigott, T.A.1
Saha, A.R.2
Ali, M.W.3
-
25
-
-
0038488945
-
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder
-
Im Druck
-
Potkin SG, Saha AR, Kujawa MJ, Carson WH, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psych 2003. Im Druck.
-
(2003)
Arch Gen Psych
-
-
Potkin, S.G.1
Saha, A.R.2
Kujawa, M.J.3
Carson, W.H.4
-
27
-
-
4244071100
-
Dopamine receptors and transporters in Parkinson's disease and schizophrenia
-
Seeman P, Niznik HB. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J 1996;274:740-3.
-
(1996)
FASEB J
, vol.274
, pp. 740-743
-
-
Seeman, P.1
Niznik, H.B.2
-
28
-
-
0035204601
-
Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, Part 1. "Goldilocks" actions at dopamine receptors
-
Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, Part 1. "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 2001;62:841-2.
-
(2001)
J Clin Psychiatry
, vol.62
, pp. 841-842
-
-
Stahl, S.M.1
-
29
-
-
0003096276
-
Aripiprazole and risperidone versus placebo in schizophrenia
-
Yeoung P, McQuade RD, Carson WH, Saha A, et al. Aripiprazole and risperidone versus placebo in schizophrenia. Eur Psychiatry 2002;17(Suppl 1):102-3.
-
(2002)
Eur Psychiatry
, vol.17
, Issue.SUPPL. 1
, pp. 102-103
-
-
Yeoung, P.1
McQuade, R.D.2
Carson, W.H.3
Saha, A.4
-
30
-
-
0035983682
-
3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole: A study using positron emission tomography and (11C)raclopride
-
3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole: a study using positron emission tomography and (11C)raclopride. Neuropsychopharmacology 2002;27:248-59.
-
(2002)
Neuropsychopharmacology
, vol.27
, pp. 248-259
-
-
Yokoi, F.1
Gründer, G.2
Biziere, K.3
|